{"name":"Akesobio Australia Pty Ltd","slug":"akesobio-australia-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AK-104","genericName":"AK-104","slug":"ak-104","indication":"Other","status":"phase_1"},{"name":"AK-105","genericName":"AK-105","slug":"ak-105","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AK120","genericName":"AK120","slug":"ak120","indication":"Solid tumors (specific indication under clinical evaluation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"AK-104","genericName":"AK-104","slug":"ak-104","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AK-105","genericName":"AK-105","slug":"ak-105","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AK120","genericName":"AK120","slug":"ak120","phase":"phase_3","mechanism":"AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens.","indications":["Solid tumors (specific indication under clinical evaluation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOa2dGWEVIbVFNZl9YLWZBZ1dKV2dPMUxWOVhDcjc3dDNmNFZmdWs2RDdOdkFVX09pb3d3VXA3d1U3czdrcVJJSzdqMG9fb2VzNnd0Rks0dFBwYVNHVkNXUnFoMGpwdVBhQzFuWW5xckt3S2lkOXhhVkwwOXRkbF9Sc2J0VDFNb3k0aEk4VXc5eG9nVllZckJNT29maXQ0TDJ0cGVrQ1YtcnBJSEZwUWFNeWVkMHVBdXhQNlgtQ1J0RGdiMDZpQ3FDTVliLTItak1GaS1naHFnbVRObEMzS0J0YWQ1ZkNyRHpoTmJzbWx2d1QtU0NubGVyUUdiWTY1SUlHaGhhd0lMTVlFUDg3MjE2WUlGU3lTWk9fTC1WWl83VVBBRTBLcG5heEF6ajBXRlJ1aXdJ?oc=5","date":"2023-04-11","type":"deal","source":"PR Newswire","summary":"Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia - PR Newswire","headline":"Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibo","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}